Motley Fool  Mar 13  Comment 
New data and bargain pricing could reshape the cholesterol treatment market.
FierceBiotech  Mar 12  Comment 
Sanofi has turned down the chance to opt into Alnylam’s primary hyperoxaluria type 1 drug lumasiran. The French pharma’s decision gives Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation.
Wall Street Journal  Mar 10  Comment 
The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients.
FiercePharma  Mar 9  Comment 
ORLANDO, Fla.—As the American College of Cardiology's annual meeting kicked off in Orlando on Saturday, all eyes turned to Sanofi and Regeneron, who reported their PCSK9 drug Praluent reduced the risk of cardiovascular events by 15%—as well as...
FiercePharma  Mar 8  Comment 
The Dengvaxia mess in the Philippines is still actively evolving, but the vaccine’s maker Sanofi, with seemingly unyielding faith in its safety and efficacy, will soon decide whether to file for approval in the U.S.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki